Pemvidutide is an experimental GLP-1 and glucagon receptor co-agonist in phase 3 trials, not approved and banned in sport as an unapproved substance. Studies in people, mostly with fatty liver disease, tested it on liver fat and weight, and tracked side effects. PepBank shows 26 results on pemvidutide from 3 studies in people, and 17 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.
Also known as ALT-801, MD-1373, MD1373, SP-1373, SP1373
| What it is | Conjugate, 29 amino acids |
|---|---|
| Approval | Not approved for any use |
| In sport | Banned in sport (WADA S0) |
| Studies | 5 studies with results. 4 of them gave pemvidutide, with 43 results. 26 in people17 in animals |
| Best study in people | Randomized controlled trial with 171 people (2025) |
| Clinical trials | 8 registered: 2 active or planned, 0 with posted results |
A GLP-1 and glucagon receptor co-agonist studied for metabolic and liver disorders.
Amino acids in one chain
A registered trial of pemvidutide started (NCT04561245).
The oldest paper on pemvidutide in PepBank is from 2022.
The key facts about the molecule. Long codes are in the closed section below.
Three-letter sequenceHis-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Ala-Ala-Lys-Glu-Phe-Ile-Gln-Trp-Leu-Leu-Gln-Thr
Results grouped by what the studies measured. Each card shows where its results come from.
In MASH, pemvidutide increased disease resolution without worsening fibrosis compared with placebo. Lancet, 2025
In MASLD, pemvidutide reduced body weight compared with placebo. Journal of hepatology, 2025
In mice, ALT-801 reduced blood cholesterol more than semaglutide. Scientific reports, 2022
In mice, ALT-801 reduced galectin-3 compared with vehicle. Scientific reports, 2022
Studies in people come first, then studies in animals and in the lab.
ClinicalTrials.gov lists 8 trials of pemvidutide. 2 are active or planned, and 0 have posted results. PepBank does not show trial results.
Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.
No approved medicine contains it.
No approved medicine contains it.
On the 2026 Prohibited List, section S0.
No. Not approved for any use. Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 27 Oct 2026). Banned in sport (WADA S0).
Laws and labels change, so check the regulator for the current status.
PepBank has 7 safety results from studies of pemvidutide. 7 of them come from studies in people.
The doses that these studies used. They are not recommendations.
| Dose as reported | Class | Species | Route | Duration | Design | Source |
|---|---|---|---|---|---|---|
| 1·8 mg | Human | human | subcutaneous once weekly | 24 weeks | Randomized trial in people · n = 171 | Noureddin 2025 |
| 1·2 mg | Human | human | subcutaneous once weekly | 24 weeks | Randomized trial in people · n = 127 | Noureddin 2025 |
| 1.2 mg | Human | human | subcutaneous once weekly | 12 weeks | Randomized trial in people | Harrison 2025 |
| 1.8 mg | Human | human | subcutaneous once weekly | 12 weeks | Randomized trial in people | Harrison 2025 |
| 2.4 mg | Human | human | subcutaneous once weekly | 12 weeks | Randomized trial in people | Harrison 2025 |
| 1.2 mg | Human | human | subcutaneous once weekly | 24 weeks | Randomized trial in people | Browne 2025 |
| 1.8 mg | Human | human | subcutaneous once weekly | 24 weeks | Randomized trial in people | Browne 2025 |
| 2.4 mg | Human | human | subcutaneous once weekly | 24 weeks | Randomized trial in people | Browne 2025 |
| 1.2 mg, 1.8 mg or 2.4 mg | Human | human | subcutaneous once weekly | 12 weeks | Randomized trial in people | Harrison 2025 |
| 1.2 mg, 1.8 mg or 2.4 mg | Human | human | subcutaneous once weekly | 24 weeks | Randomized trial in people | Browne 2025 |
The answer links to every study it uses.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Ask your AI about pemvidutide
Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated